Ha ha hold tight guys and you will be rewarded.

Thks so much @Trevor777 for your positive insight.

Still holding tight.
Hopefully can get final dividen and bonus too.
Ha ha.

Ha ha guys,
Its very good news.
Start of up trend tomorrow.

Good morning guys.
Esceram is for mid to long term investment.
Be very patient guys.
Handformers manufacturing is very specialised products and needed long years experience in order to develope
the right products.
Esceram is the only listed company doing handformers in malaysia.
Correct me if l am wrong.
The whole gloves companies in the world needed handformers for their operation and the replacement market is huge for handformers.

Both dividens ex date is 30june 2021.

Good morning guys.
Ha ha got special dividen and
final dividen.
So today scomnet should wake up from sleep guys.

https://www.reuters.com/world/asia-pacific/singapore-tightens-covid-19-curbs-social-gatherings-dining-2021-05-14/

Ha ha ...good morning guys.
There is a possibility that dnex will crawl higher after 20th may.
Not buy or sell call.
Stay home stay safe folks.

Ha ha..good morning guys.
Fully agreed with Allenlee comment.
Stock investing need patient guys and should know how to control emotion.

Ha ha..don't worry so much guys.
For those praying and hoping dnex price to go down to 50 cents bcos they had missed the train.
Patient guys and you will be rewarded.

Ha ha..guys
Very potential counter to explode in mid to long terms.
Do not missed this gem guys.
Well managed company.
Not buy or sell call.

Ha ha..l think @cikam is correct.
Hlt will move higher if carepls moved up.
Good news for carepls to move to main board.

Ha ha..
Do not bad mouth in fasting month .

Bravo!!! Scomnet.
Improved qtr result very likely with new expansion factory and new products.
Not buy or sell call.

Good morning folks.
This time the train is moving faster.
Lets jump quickly or will missed it.
Ha Ha that is exactly happened to pak tua.

Ha Ha.. Hlt coming back.
Once big 4 moved
Hlt will limit up.
More cases covid reported worldwide abd malaysia too.
Pls take care guys.

You are absolutely right!
Borntospeculate.

Lets talk on dnex prospect folk.

Good morning folks.
Any sifu can advise on the new esos price?

Basis of determining the subscription price Subject to any adjustments made under the New ESOS By-Laws and pursuant to the Listing Requirements, the subscription price shall be based on the 5-day VWAP of DNeX Shares immediately preceding the Date of Offer, with a discount of not more than 10% or such other percentage of discount as may be permitted by any prevailing guideline issued by Bursa Securities and/or any other relevant authorities as amended from time to time, as determined by the Board upon recommendation of the ESOS Committee which shall be binding and conclusive. 2.2.6 Ranking of the New ESOS Options and new DNeX Shares to be issued arising from the exercise of the New ESOS Options The New ESOS Options will not carry any voting rights or rights to participate in any form of distributions or further offer of securities in DNeX until and unless they are exercised into new DNeX Shares. The new DNeX Shares to be allotted and issued upon the exercise of the New ESOS Options will, upon allotment, issuance and full payment, rank equally in all respects with the existing DNeX Shares, save and except that the new DNeX Shares will not be entitled to any dividends, rights, allotments and/or any other forms of distribution where the entitlement date precedes the relevant date of allotment and issuance of the new DNeX Shares. The new DNeX Shares will be subject to all provision in the Constitution of the Company and Listing Requirements, if any. 2.2.7 Holding of DNeX Shares Pursuant to Paragraph 8.20 of the Listing Requirements, an eligible Director who is a non-executive Director of DNeX and/or any of its subsidiaries, which are not dormant, shall not sell, transfer or assign the DNeX Shares obtained through the exercise of the New ESOS Options offered to him/ her within 1 year from the Date of Offer. Save for the non-executive Directors, the new DNeX Shares allotted and issued to the grantees pursuant to the exercise of the New ESOS Options will not be subject to any holding period or restriction on transfer, disposal and/or assignment. 2.2.8 Listing and quotation for the new DNeX Shares to be issued arising from the exercise of the New ESOS Options Bursa Securities had vide its letter dated 25 February 2021, approved the listing and quotation for such number of new DNeX Shares, representing up to 5% of the total number of DNeX Shares (excluding treasury shares, if any) to be issued arising from the exercise of the New ESOS Options on the Main Market of Bursa Securities, subject to the conditions as disclosed in Section 6of this Circular.

All in buy this counter.

http://www.dnex.com.my/newsroom/dnex-partners-with-china-party-towards-more-efficient-cross-border-trade-between-malaysia-and-china

For counter less than rm1.00,
30cents is max gain for one day.
For counter more than rm1.00,
30% is the max gain for one day.

Ha ha, dnex given extension date by bursa for balance pp.
This is good news for dnex existing shareholders bcos there is a possibility can list higher pp prices later.

X
Newbie318 "The stock market is a device for transffering money from the impatient to the patient".
By Warrent Buffet.

https://www.klsescreener.com/v2/announcements/view/3303515

Bravo!!!! Esceram.
Very strong fundamental company.

Don't miss this tgv train.
Its going faster and faster.

Bravo!!!!!!!!! Scomnet.
Stock pick by many lnvestment bank
for 2021.

Bravo!!!!scomnet...
2021 stock pick.

"The stock market is a device for transffering money from the impatient to the patient".
By Warrent Buffet.

Just be patient guys,you will be rewarded.

Good morning guys,
Get ready for market to open.
Gloves rally today,leading by big brother topglove.
Esceram will follow too..ha ha.

Tomorrow high possibilities for all gloves counter will up leading by topglove.
Good luck atg.

Fully agreed.
Hold tight guys..

Gloves play possible starting tomorrow,leading by topglove.
Hopefully esceram will follow too.
It's very positive feeling in topglove forumers.

https://www.klsescreener.com/v2/news/view/773081

Stockiss,koolset,kk have done very good job.
Thanks you very much for giving positive feed back on at glove.
Just be patient guys.

For medium and long term investors,scomnet is very good to hold.

Uncle Tekseng is waking up from long sleep guys.
Don't miss this uptrending guys.

Good morning folks,
Don't miss Esceram this time.

Followed by esceram ceramic folks, don't forget yaa!

Technical tracker - HLIB Retail Research – 4 Jan 2021*


*TEKSENG (RM0.66 – Not-rated) - A new lease of life*


*2020 would be a transformational year for TEKSENG after incurring steep losses in FY18-19 (driven by the impairment loss recognised at its solar division), premised on rising demand for PVC products on surging usage for household products, office and home furniture during Covid-19 WFH practice, timely capacity expansion (+150% to 820MT pa) to meet growing demand for PP non-woven products and diversification into PPE and medical industry*


*The stock is trading at 7.4x FY21 P/E (59% below its peers and 52% lower than its 5-year average), supported by a strong FY20-22 earnings CAGR of 18%, attractive FY21-22 DY of 4.5% and solid NCPS of RM10.5sen*



*Trend* Pending a downtrend line breakout


*R1-R2*: 0.70-0.76


*LT objective*: 0.80


*S1-S2*: 0.63-0.61


*Cut*: 0.595

on from 2021 onwards. 
a) For customer A, the spotlight will be on its Colonoscopy GI, Gastrocopy GI and 
Duodenoscopy GI which is expected to contribute about 15-20% of incremental group 
revenue from 2021 onwards. The overwhelming demand for its endoscopy cables, 
which has seen a tremendous sales leap of several folds compared to pre-MCO 
levels, will also significantly enhance earnings. 
b) For customer E, SMP will continue to benefit from the expansion of medical 
orderbook with organic yoy growth of at least 10-16% for its existing products, while 
there are also about seven projects with customer E on hand. 
c) For customer M, the mass production of its D’Clot HD Catheter has been pushed 
back due to the delays in product training processes amid COVID-19 disruptions. 
That said, this is just a temporary setback and production should be able to start 
immediately once the doctors are able to conduct physical training and complete the 
production requirements. 
d) We also understand that SMP has secured a new client with a prominent new blood 
clotting product for dialysis. While Scomnet recently presented the product to FDA in 
Los Angeles, the approval results should be announced in Feb/Mar 21. Notably, the 
US Navy Force has signed an agreement to receive supply of this blood clotting 
product. We believe this product can contribute positively to SMP’s earnings as early 
as 2Q21 next year immediately after FDA approval, given that SMP has already 
allocated the facilities and equipment required for commercial production. 
 Automobile segment: Growth trajectory from customer P. The emergence of 
Supercomal Advanced Cables’ (SAC) latest key customer P will enhance the growth of 
Scomnet’s automobile segment. The agreement from this customer, which allows SAC to 
supply wire harnessing and fuel tanks (higher margin), is expected to contribute about 20- 
30% incremental revenue to SAC’s current revenue base in 2021, with subsequent years 
to see higher revenue contributions. 2021’s earnings growth will be backed by new 
revenue streams from this customer. We also understand that customer P has recently 
put in another RM6.6m capex into SAC to purchase wire harness and fuel tank 
production equipment.

07/12/2020 6:25 PM

Supercomnet Technologies (SCT MK) 
Staging For A Stronger Comeback 
3Q20 was an uneventful quarter dragged by forex losses, cost overrun and higher 
raw material cost for a new project start-up. That said, we understand these were just 
temporary setbacks which should not recur after the improvement in learning curve. 
Scomnet is staging for a stronger comeback,backed by strong orderbook visibility 
from its broad spectrum of key clients. Maintain BUY with target price of RM2.40. 
RESULTS HIGHLIGHTS 
 A temporary blip. Supercomnet Technologies (Scomnet) recorded a dismal 3Q20 core 
net profit of RM5.5m (+3.5% qoq, +19.6 yoy), bringing 9M20 core net profit to Rm13.8m 
which only made up 51% of our full-year estimate. Nevertheless, 3Q20 revenue grew 7.8% 
yoy to RM37.8m, backed by stronger sales from both the medical and automobile 
segments. 
 Bottom-line shortfall and margin downtick on exceptional outflows. Despite stronger 
revenue in the quarter, we noticed a plunge in net margin that impacted the bottom-line 
numbers. On a yoy basis, the slight decline in net margin (-1.1% yoy) was mainly due to 
labour and raw material cost overrun, driven by one of its key medical clients’ urgent 
demand surge for its endoscope cable. The rejection rate of this product spiked during the 
quarter, causing higher wastage of raw materials as well as overtime shifts to fulfil the 
overwhelming demand. All that being said, we understand that all these are non-recurring 
items as management has taken the necessary steps to achieve better efficiency with cost 
normalisation expected from 4Q20 onwards. 
 More clarity on SMP’s robust orderbook guidance... Our recent channel check with 
management revealed that orderbook volume for Scomnet’s medical segment, 
Supercomal Medical Products (SMP), remains strong, with orderbook visibility until 2Q21 
and 1Q22 for key clients – customer E and customer A respectively. Note that both 
customers made up about 90% of SMP’s revenue in 2019. 
 …but slight disruption from COVID-19 impact. Due to the COVID-19 disruption, there 
are some reduction in orders volume from its customer M. Vis-à-vis the decent sales 
projection from this customer which could boost its earnings by 25% from 3Q20 onwards, 
the mass production has been delayed on COVID-19 disruption. Nevertheless, the 
shortfall of revenue contribution from this customer was partially offset by stronger demand 
from customer A and customer E.

07/12/2020 6:25 PM



bigearl  Multi-pronged catalysts to sustain supercharged growth beyond 2021. We believe 
Scomnet will emerge as one of the most prominent global healthcare proxies in Malaysia 
and poised to deliver explosive earnings in FY21. This will be mainly driven by: a) resilient 
earnings visibility from its strong medical orderbooks on hand; b) incremental revenue from 
new medical products (D’Clot Catheter, Colonoscopy GI and Gastroscopy GI which will begin 
mass production in 1Q21; customer M’s D’Clot and new clients’ blood clotting product); c) 
near-term capacity expansion to fulfil explosive demand for medical segment’s products; d) 
significant contribution from new automobile client – customer P from 3Q21 onwards; and e) 
transfer to healthcare sector and mainboard listing which could catalyse a potential valuation 
rerating. 
 Maintain BUY with a target price of RM2.40. Post meeting, we have trimmed our 2020- 
21 revenue forecasts by 12% and 10% respectively to reflect lower contributions from 
Mermaid Medical and PSA on the slower orderbook projections. We are also assuming a 
full conversion of existing warrants into our valuations, factoring in share base of 857.3m 
shares and theoretical cash increment of RM140m. In terms of valuation (refer RHS 
valuation table), we have pegged our target price to 35x 2021F PE, its 3-year mean and at 
a discount to Bursa Malaysia Healthcare Index of 43x. 
INVESTMENT HIGHLIGHTS 
 Medical segment: SMP will see its full potential in FY21. SMP’s growth will be fuelled 
by several new products which are poised for com

Bravo!!! Tekseng,
Very undervalue counter.

Tekseng waking up folks.

https://www.klsescreener.com/v2/news/view/773059/glove-makers-in-for-a-good-run-this-year

https://klse.i3investor.com/blogs/rubberglove_y2023/2020-12-27-story-h1538400349-AT_Glove_0072_Production_Line_Trial_Step_4.jsp